VGX-1027 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "VGX-1027" in Chinese language version.

refsWebsite

Global rank Chinese rank

6nih.gov

4^th place

5^th place

6doi.org

2^nd place

23^rd place

2semanticscholar.org

11^th place

332^nd place

1handle.net

102^nd place

492^nd place

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clinical Immunology. June 2007, 123 (3): 311–23. PMID 17449326. doi:10.1016/j.clim.2007.03.004.
Cha JJ, Hyun YY, Lee MH, Kim JE, Nam DH, Song HK, et al. Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology. June 2013, 154 (6): 2144–55. PMID 23568555. doi:10.1210/en.2012-2080 .
Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, Fogarty CL, et al. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. Cell Death & Disease. May 2015, 6 (5): e1752. PMC 4669704 . PMID 25950482. doi:10.1038/cddis.2015.125.
Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, et al. Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects. Clinical Pharmacology in Drug Development. March 2016, 5 (2): 91–101. PMID 27138022. S2CID 22577185. doi:10.1002/cpdd.193.
Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. Protective effects of VGX-1027 in PM_2.5-induced airway inflammation and bronchial hyperresponsiveness. European Journal of Pharmacology. January 2019, 842: 373–383. PMID 30419239. S2CID 53292202. doi:10.1016/j.ejphar.2018.11.010. hdl:10044/1/66292 .
Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Alasmari F, Alasmari AF, et al. The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4⁺ T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T⁺ Itpr3^tf/J mice. Life Sciences. November 2019, 237: 116930. PMID 31610190. doi:10.1016/j.lfs.2019.116930.

handle.net (Global: 102^nd place; Chinese: 492^nd place)

hdl.handle.net

Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. Protective effects of VGX-1027 in PM_2.5-induced airway inflammation and bronchial hyperresponsiveness. European Journal of Pharmacology. January 2019, 842: 373–383. PMID 30419239. S2CID 53292202. doi:10.1016/j.ejphar.2018.11.010. hdl:10044/1/66292 .

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clinical Immunology. June 2007, 123 (3): 311–23. PMID 17449326. doi:10.1016/j.clim.2007.03.004.
Cha JJ, Hyun YY, Lee MH, Kim JE, Nam DH, Song HK, et al. Renal protective effects of toll-like receptor 4 signaling blockade in type 2 diabetic mice. Endocrinology. June 2013, 154 (6): 2144–55. PMID 23568555. doi:10.1210/en.2012-2080 .
Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, Fogarty CL, et al. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. Cell Death & Disease. May 2015, 6 (5): e1752. PMC 4669704 . PMID 25950482. doi:10.1038/cddis.2015.125.
Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, et al. Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects. Clinical Pharmacology in Drug Development. March 2016, 5 (2): 91–101. PMID 27138022. S2CID 22577185. doi:10.1002/cpdd.193.
Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. Protective effects of VGX-1027 in PM_2.5-induced airway inflammation and bronchial hyperresponsiveness. European Journal of Pharmacology. January 2019, 842: 373–383. PMID 30419239. S2CID 53292202. doi:10.1016/j.ejphar.2018.11.010. hdl:10044/1/66292 .
Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Alasmari F, Alasmari AF, et al. The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4⁺ T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T⁺ Itpr3^tf/J mice. Life Sciences. November 2019, 237: 116930. PMID 31610190. doi:10.1016/j.lfs.2019.116930.

semanticscholar.org (Global: 11^th place; Chinese: 332^nd place)

api.semanticscholar.org

Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, et al. Safety, bioavailability, and pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects. Clinical Pharmacology in Drug Development. March 2016, 5 (2): 91–101. PMID 27138022. S2CID 22577185. doi:10.1002/cpdd.193.
Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. Protective effects of VGX-1027 in PM_2.5-induced airway inflammation and bronchial hyperresponsiveness. European Journal of Pharmacology. January 2019, 842: 373–383. PMID 30419239. S2CID 53292202. doi:10.1016/j.ejphar.2018.11.010. hdl:10044/1/66292 .

VGX-1027 (Chinese Wikipedia)

doi.org (Global: 2nd place; Chinese: 23rd place)

handle.net (Global: 102nd place; Chinese: 492nd place)